Moreover, screening approaches using biosensors expressing mutational libraries of chimeric receptors could be used to identify molecules with improved binding profiles e.g. preferential interaction to certain ligands or to predict antibody or drug escape mutations in virus attachment proteins and membrane-resident tumor therapy targets, respectively. This evidence concerns the gene PROS1 and neoplasm.